Navigation Links
AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
Date:4/21/2009

>Entitled, "In vitro profiling of the potent and selective PI3K inhibitor, AEZS-126", I. Seipelt, M. Gerlach, L. Blumenstein, G. Mueller, M.Teifel, E. Polymeropoulos and E. Guenther, the poster outlines the key in vitro characteristics of this compound that led to its selection for in vivo development.

Results

AEterna Zentaris has identified a new generation of low molecular weight pyridopyrazine compounds as highly potent and selective inhibitors of class I PI3Ks. Presented here, are the key in vitro characteristics of AEZS-126 that led to its selection for in vivo development. AEZS-126 inhibits PI3Ka with an IC50 value of 10nM and proved to be a potent inhibitor of Akt phosphorylation in cellular assays. Mode-of-action studies showed that AEZS-126 acts as an ATP competitive compound. The in vitro antiproliferative activity against different human tumor cell lines (MDA-MB 468, U87, Hct116, PC-3, A549 and others) was determined, with EC50 values in the nanomolar range.

Conclusion

The optimization of AEterna Zentaris' pyridopyrazine lead structure regarding kinase selectivity, cellular potency and ADMET properties, led to the identification of AEZS-126, a compound which has a favorable in vitro pharmacologic profile for further in vivo profiling.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which c
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 Bionomics Limited ... the DisrupTOR-1 trial of BNC105 in patients with metastatic ... Orlando, Florida . The data will ... the City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and IL-8 ...
(Date:2/27/2015)...  Steep Hill, the industry leader in cannabis testing ... open a full service medical cannabis quality assurance laboratory ... advanced scientific tools and methodology to the state, for ... currently the only laboratory licensed by the New Mexico ... in order to meet the recently adopted regulatory requirements ...
(Date:2/26/2015)... Feb. 26, 2015  23andMe, the leading personal genetics ... as Privacy Officer and Corporate Counsel. Black brings ... laws as well as health care regulations. As a ... be responsible for reviewing, updating and enhancing the company,s ... and abroad. She joined the company January 5, 2015 ...
(Date:2/26/2015)... , Feb. 26, 2015 Protiviti ( www.protiviti.com ... version of the Governance Portal , designed to ... and compliance (GRC) tasks across multiple business units and ... to help customers better align their controls with the ... Commission ) requirements. In response to client feedback, Protiviti ...
Breaking Biology Technology:New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 223andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3
... 7 Amsterdam Molecular,Therapeutics (Euronext: AMT), a leader ... the treatment of the first patient in a ... targets,lipoprotein lipase deficiency (LPLD), a seriously debilitating and,potentially ... randomized controlled trial has been designed to gather ...
... Kendle (Nasdaq: KNDL ), a leading, global ... or $0.06 per share for the first quarter 2009 compared ... share for the first quarter 2008. On a pro forma ... $0.47 per diluted share compared with $0.38 per diluted share ...
... Amgen (Nasdaq: AMGN ), today announced ... Stockholders, held at The St. Regis Hotel, San Francisco, ... represented at the meeting.The director nominees: David Baltimore, Frank ... Vance D. Coffman, Frederick W. Gluck, Frank C. Herringer, ...
Cached Biology Technology:AMT Starts Preregistration Trial for Glybera(TM) 2AMT Starts Preregistration Trial for Glybera(TM) 3Kendle Announces First Quarter 2009 Results 2Kendle Announces First Quarter 2009 Results 3Kendle Announces First Quarter 2009 Results 4Kendle Announces First Quarter 2009 Results 5Kendle Announces First Quarter 2009 Results 6Kendle Announces First Quarter 2009 Results 7Kendle Announces First Quarter 2009 Results 8Amgen Announces Voting Results Of Annual Meeting Of Stockholders 2
(Date:2/19/2015)... , Feb .19, 2015 Research and Markets ... addition of the "Military Electro-Optical / Infrared ... Technology, by Platform - Forecast to 2020" ... military electro-optical/infrared systems market is expected to reach ... of 7.71%. This report segments the ...
(Date:2/13/2015)... 2015 ACT Genomics Co., Ltd., a ... transform cancer genomic information into precision diagnosis and ... raised US$ 8 million in the its first private ... Taipei, Taiwan , ACT Genomics has developed ... aim to implement next generation sequencing (NGS) and ...
(Date:2/12/2015)... OXFORD, Conn. , Feb. 12, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... it has filed provisional patent 62/113114 for ... MULTIPLE DEVICES. The patent further establishes NXT-ID,s ... to its intellectual property portfolio the ability for multiple ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3ACT Genomics Raises $8 Million in its First Private Funding Round 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3
... carbon dioxide out of the air and covert it into ... light as their energy source. Chemists would also like to ... their synthetic reactions, but it doesn’t work just like that. ... Institute for Colloids and Interfaces has now taken an important ...
... have discovered a new source of stems cells and ... vessel, nerve and liver cells in the laboratory. The ... cells from the amniotic fluid that surrounds developing embryos ... is that these cells will provide a valuable resource ...
... by scientists for a dog snapper is actually a ... region of the South Atlantic Ocean. , The international ... a new snapper species that belongs to the Lutjanidae ... and Kenyon Lindeman of Environmental Defense. The study published ...
Cached Biology News:Progress toward artificial photosynthesis? 2Scientists discover new, readily available source of stem cells 2Scientists discover new, readily available source of stem cells 3New species of snapper discovered in Brazil 2
...
Cag-A (IgG) -Ab EIA Sample Size: 10 l...
... Recombinant Ribonuclease Inhibitor is a ... ribonucleases such as RNase A. ... Recombinant Ribonuclease Inhibitor is an ... weight ~52 kDa. RNaseOUT inhibits ...
... inhibitor) is a 50 kDa ... RNase activity. It does not ... , Inhibits RNase activity, ... , Lacks DNA endonuclease ...
Biology Products: